Relvar Ellipta 200/25mcg is a combination dry powder inhaler containing a synthetic corticosteroid, fluticasone furoate, and a long-acting beta-agonist, vilanterol.
 
This medication is approved for the regular treatment of asthma in adults and adolescents aged 12 years or above, as well as for the symptomatic treatment of chronic obstructive pulmonary disease (COPD) in adults.
 
With once-daily use, its dual anti-inflammatory and bronchodilatory mechanism helps improve lung function, relieve respiratory symptoms such as shortness of breath and wheezing, and reduce the risk of exacerbations. It is suitable for patients who, following medical assessment, require combination maintenance therapy.